Handelen Agenus - AGEN CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.0268 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Agenus Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.5867 |
Open* | 1.5767 |
1-Jaarlijkse Verandering* | -0.84% |
Dagelijks bereik* | 1.5667 - 1.6166 |
52 wekelijks bereik | 1.23-3.31 |
Weekgemiddelde volume (10 dagen) | 3.89M |
Gemiddeld volume (3 maanden) | 107.87M |
Marktkapitalisatie | 558.20M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 348.88M |
Omzet | 94.99M |
EPS | -0.81 |
Dividend (opbrengst %) | N/A |
Beta | 1.41 |
Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 1.6066 | 0.0300 | 1.90% | 1.5766 | 1.6266 | 1.5467 |
Jun 1, 2023 | 1.5867 | 0.0499 | 3.25% | 1.5368 | 1.6166 | 1.4868 |
May 31, 2023 | 1.5467 | 0.0898 | 6.16% | 1.4569 | 1.5467 | 1.4270 |
May 30, 2023 | 1.4569 | 0.0199 | 1.38% | 1.4370 | 1.4869 | 1.4170 |
May 26, 2023 | 1.4370 | 0.0300 | 2.13% | 1.4070 | 1.4370 | 1.3671 |
May 25, 2023 | 1.4170 | 0.0000 | 0.00% | 1.4170 | 1.4270 | 1.3571 |
May 24, 2023 | 1.3970 | -0.0998 | -6.67% | 1.4968 | 1.4968 | 1.3870 |
May 23, 2023 | 1.5168 | 0.0499 | 3.40% | 1.4669 | 1.5867 | 1.4669 |
May 22, 2023 | 1.4769 | 0.0799 | 5.72% | 1.3970 | 1.4869 | 1.3970 |
May 19, 2023 | 1.3871 | -0.0399 | -2.80% | 1.4270 | 1.4569 | 1.3870 |
May 18, 2023 | 1.4070 | -0.0299 | -2.08% | 1.4369 | 1.4869 | 1.3771 |
May 17, 2023 | 1.4669 | 0.0599 | 4.26% | 1.4070 | 1.4769 | 1.3471 |
May 16, 2023 | 1.3871 | -0.0898 | -6.08% | 1.4769 | 1.4869 | 1.3771 |
May 15, 2023 | 1.5068 | 0.1098 | 7.86% | 1.3970 | 1.5368 | 1.3771 |
May 12, 2023 | 1.4070 | -0.0100 | -0.71% | 1.4170 | 1.4170 | 1.3771 |
May 11, 2023 | 1.3871 | -0.1097 | -7.33% | 1.4968 | 1.4968 | 1.3771 |
May 10, 2023 | 1.5268 | 0.0200 | 1.33% | 1.5068 | 1.6066 | 1.4769 |
May 9, 2023 | 1.4869 | -0.0698 | -4.48% | 1.5567 | 1.5867 | 1.4270 |
May 8, 2023 | 1.5867 | -0.0099 | -0.62% | 1.5966 | 1.6166 | 1.5467 |
May 5, 2023 | 1.5567 | 0.0100 | 0.65% | 1.5467 | 1.6066 | 1.5367 |
Agenus Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Thursday, June 8, 2023 | ||
Tijd (UTC) (UTC) 17:00 | Land US
| Evenement Agenus Inc at Jefferies Healthcare Conference Agenus Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Tijd (UTC) (UTC) 19:30 | Land US
| Evenement Agenus Inc Annual Shareholders Meeting Agenus Inc Annual Shareholders MeetingForecast -Previous - |
Monday, June 12, 2023 | ||
Tijd (UTC) (UTC) 14:30 | Land US
| Evenement Agenus Inc Annual Shareholders Meeting Agenus Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 Agenus Inc Earnings Release Q2 2023 Agenus Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Tijd (UTC) (UTC) 13:30 | Land US
| Evenement Q3 2023 Agenus Inc Earnings Release Q3 2023 Agenus Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 98.024 | 295.665 | 88.17 | 150.048 | 36.7836 |
Inkomsten | 98.024 | 295.665 | 88.17 | 150.048 | 36.7836 |
Totale bedrijfskosten | 279.388 | 263.721 | 208.125 | 220.185 | 171.372 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 81.007 | 76.359 | 59.218 | 46.041 | 37.3397 |
Onderzoek & Ontwikkeling | 186.691 | 178.608 | 142.617 | 168.339 | 124.6 |
Other Operating Expenses, Total | 5.805 | -1.335 | |||
Bedrijfsresultaat | -181.364 | 31.944 | -119.955 | -70.137 | -134.588 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -61.863 | -65.719 | -61.078 | -41.451 | -25.2726 |
Overige, Netto | 12.571 | 5.051 | -1.858 | 0.028 | -2.18328 |
Netto inkomen voor belastingen | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
Netto inkomen na belastingen | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
Netto inkomen voor extra. Posten | -220.074 | -23.926 | -180.914 | -107.657 | -159.692 |
Netto inkomen | -220.074 | -23.926 | -180.914 | -107.657 | -159.692 |
Total Adjustments to Net Income | -0.212 | -0.211 | -0.209 | -0.208 | -0.20684 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
Verwaterd Netto Inkomen | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
Verwaterd Gewogen Gemiddelde Aandelen | 281.743 | 228.919 | 172.504 | 134.982 | 110.772 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.78187 | -0.10544 | -1.04996 | -0.79911 | -1.44349 |
Dividends per Share - Common Stock Primary Issue | |||||
Verwaterde Genormaliseerde Winst per Aandeel | -0.77499 | -0.13251 | -1.0342 | -0.79911 | -1.3463 |
Totale buitengewone posten | 0 | ||||
Ongebruikelijke uitgaven (inkomsten) | 1.937 | -6.197 | 2.72 | 0 | 10.7666 |
Minderheidsbelang | 10.582 | 4.798 | 1.977 | 3.903 | 2.3519 |
Kosten van opbrengsten, totaal | 10.568 | 3.47 | 2.349 | ||
Brutowinst | 87.456 | 292.195 | 85.821 | ||
Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | -0.815 | 11.481 | 1.221 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 22.902 | 28.386 | 22.772 | 20.926 | 25.941 |
Inkomsten | 22.902 | 28.386 | 22.772 | 20.926 | 25.941 |
Kosten van opbrengsten, totaal | 2.294 | 7.693 | 0.308 | 2.024 | 0.543 |
Brutowinst | 20.608 | 20.693 | 22.464 | 18.902 | 25.398 |
Totale bedrijfskosten | 77.243 | 88.08 | 64.417 | 65.491 | 61.402 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 18.237 | 25.036 | 18.105 | 18.914 | 18.953 |
Onderzoek & Ontwikkeling | 57.118 | 53.279 | 46.011 | 44.96 | 42.442 |
Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | -0.406 | 0.135 | -0.007 | -0.407 | -0.536 |
Bedrijfsresultaat | -54.341 | -59.694 | -41.645 | -44.565 | -35.461 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -16.592 | -17.325 | -15.607 | -13.731 | -15.199 |
Overige, Netto | 0.04 | 2.917 | 0.537 | 9.061 | 0.056 |
Netto inkomen voor belastingen | -70.893 | -74.102 | -56.715 | -49.235 | -50.604 |
Netto inkomen na belastingen | -70.893 | -74.102 | -56.715 | -49.235 | -50.604 |
Minderheidsbelang | 2.639 | 3.009 | 2.493 | 2.801 | 2.279 |
Netto inkomen voor extra. Posten | -68.254 | -71.093 | -54.222 | -46.434 | -48.325 |
Netto inkomen | -68.254 | -71.093 | -54.222 | -46.434 | -48.325 |
Total Adjustments to Net Income | -0.053 | -0.053 | -0.053 | -0.053 | -0.053 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -68.307 | -71.146 | -54.275 | -46.487 | -48.378 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -68.307 | -71.146 | -54.275 | -46.487 | -48.378 |
Verwaterd Netto Inkomen | -68.307 | -71.146 | -54.275 | -46.487 | -48.378 |
Verwaterd Gewogen Gemiddelde Aandelen | 317.109 | 304.462 | 286.854 | 277.033 | 258.31 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.21541 | -0.23368 | -0.18921 | -0.1678 | -0.18729 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -0.21541 | -0.22732 | -0.18921 | -0.1678 | -0.18729 |
Ongebruikelijke uitgaven (inkomsten) | 1.937 | 0 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 213.122 | 331.974 | 113.783 | 86.536 | 74.8077 |
Geldmiddelen en kortetermijnbeleggingen | 193.358 | 306.923 | 99.871 | 61.808 | 53.0535 |
Geldmiddelen & Equivalenten | 178.674 | 291.931 | 99.871 | 61.808 | 53.0535 |
Korte Termijn Investeringen | 14.684 | 14.992 | |||
Totale Vorderingen, Netto | 2.741 | 1.518 | 1.157 | 16.293 | 0.93814 |
Accounts Receivable - Trade, Net | 2.741 | 1.518 | 1.157 | 16.293 | 0.93814 |
Total Inventory | 0 | 0.05549 | |||
Prepaid Expenses | 13.829 | 20.362 | 10.746 | 7.42 | 19.2648 |
Other Current Assets, Total | 3.194 | 3.171 | 2.009 | 1.015 | 1.49572 |
Total Assets | 413.556 | 465.958 | 214.514 | 155.335 | 136.401 |
Property/Plant/Equipment, Total - Net | 164.286 | 91.083 | 60.27 | 33.69 | 25.1156 |
Property/Plant/Equipment, Total - Gross | 218.361 | 141.622 | 107.471 | 76.551 | 63.1836 |
Accumulated Depreciation, Total | -54.075 | -50.539 | -47.201 | -42.861 | -38.068 |
Goodwill, Net | 25.467 | 24.876 | 25.452 | 23.188 | 22.9249 |
Intangibles, Net | 6.228 | 8.488 | 10.886 | 10.504 | 12.3382 |
Other Long Term Assets, Total | 4.453 | 9.537 | 4.123 | 1.417 | 1.21439 |
Total Current Liabilities | 188.952 | 156.943 | 129.884 | 122.209 | 68.0622 |
Accounts Payable | 40.939 | 30.486 | 17.015 | 13.564 | 13.6239 |
Accrued Expenses | 40.202 | 44.718 | 31.007 | 32.679 | 24.5513 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 8.527 | 1.063 | 1.579 | 0.794 | 0.14606 |
Other Current Liabilities, Total | 99.284 | 80.676 | 80.283 | 75.172 | 29.7409 |
Total Liabilities | 474.834 | 431.518 | 391.269 | 353.774 | 268.989 |
Total Long Term Debt | 24.854 | 13.141 | 18.945 | 13.38 | 13.2115 |
Long Term Debt | 12.584 | 12.823 | 18.879 | 13.38 | 13.2115 |
Other Liabilities, Total | 254.652 | 247.965 | 250.266 | 224.166 | 189.794 |
Total Equity | -61.278 | 34.44 | -176.755 | -198.439 | -132.588 |
Redeemable Preferred Stock | 0 | 0 | 0 | 32.8321 | |
Preferred Stock - Non Redeemable, Net | 0 | 26.917 | 26.917 | 7.04734 | |
Common Stock | 3.056 | 2.569 | 1.961 | 1.378 | 1.19996 |
Additional Paid-In Capital | 1644.66 | 1520.21 | 1257.5 | 1059.58 | 1005.18 |
Retained Earnings (Accumulated Deficit) | -1709.91 | -1489.83 | -1465.91 | -1284.99 | -1177.31 |
Other Equity, Total | 0.915 | 1.492 | 2.772 | -1.324 | -1.53937 |
Total Liabilities & Shareholders’ Equity | 413.556 | 465.958 | 214.514 | 155.335 | 136.401 |
Total Common Shares Outstanding | 305.573 | 256.898 | 196.091 | 137.818 | 119.996 |
Total Preferred Shares Outstanding | 0.03162 | 0.03162 | 0.04408 | 0.04408 | 0.05008 |
Minority Interest | 6.376 | 13.469 | -7.826 | -5.981 | -2.0783 |
Capital Lease Obligations | 12.27 | 0.318 | 0.066 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 205.689 | 213.122 | 251.432 | 288.934 | 290.483 |
Geldmiddelen en kortetermijnbeleggingen | 189.233 | 193.358 | 218.23 | 238.33 | 262.687 |
Geldmiddelen & Equivalenten | 164.819 | 178.674 | 208.354 | 228.385 | 247.709 |
Totale Vorderingen, Netto | 1.417 | 2.741 | 8.823 | 18.994 | 1.286 |
Accounts Receivable - Trade, Net | 1.417 | 2.741 | 8.823 | 18.994 | 1.286 |
Prepaid Expenses | 11.143 | 13.829 | 21.989 | 28.622 | 21.73 |
Other Current Assets, Total | 3.896 | 3.194 | 2.39 | 2.988 | 4.78 |
Total Assets | 412.854 | 413.556 | 429.019 | 456.174 | 441.305 |
Property/Plant/Equipment, Total - Net | 171.463 | 164.286 | 138.854 | 127.158 | 105.919 |
Property/Plant/Equipment, Total - Gross | 196.553 | 187.092 | 154.188 | 141 | 127.11 |
Accumulated Depreciation, Total | -56.119 | -54.075 | -53.158 | -52.389 | -51.507 |
Goodwill, Net | 25.623 | 25.467 | 23.936 | 24.438 | 24.617 |
Intangibles, Net | 5.66 | 6.228 | 6.877 | 7.722 | 7.753 |
Other Long Term Assets, Total | 4.419 | 4.453 | 7.92 | 7.922 | 12.533 |
Total Current Liabilities | 190.898 | 188.952 | 173.073 | 159.723 | 163.062 |
Accounts Payable | 46.768 | 40.939 | 39.711 | 41.002 | 34.544 |
Accrued Expenses | 35.426 | 40.202 | 30.848 | 32.064 | 35.318 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.022 | 0.575 | 13.458 | 13.699 | 14.181 |
Other Current Liabilities, Total | 107.682 | 107.236 | 89.056 | 72.958 | 79.019 |
Total Liabilities | 471.39 | 474.834 | 449.404 | 452.758 | 425.587 |
Total Long Term Debt | 12.627 | 12.584 | 0 | 0 | 0 |
Long Term Debt | 12.627 | 12.584 | 0 | 0 | 0 |
Minority Interest | 5.427 | 6.376 | 8.549 | 10.222 | 11.932 |
Other Liabilities, Total | 262.438 | 266.922 | 267.782 | 282.813 | 250.593 |
Total Equity | -58.536 | -61.278 | -20.385 | 3.416 | 15.718 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 3.417 | 3.056 | 2.949 | 2.829 | 2.667 |
Additional Paid-In Capital | 1715.29 | 1644.66 | 1614.84 | 1583.03 | 1550.24 |
Retained Earnings (Accumulated Deficit) | -1778.16 | -1709.91 | -1638.81 | -1584.59 | -1538.16 |
Other Equity, Total | 0.917 | 0.915 | 0.644 | 2.149 | 0.97 |
Total Liabilities & Shareholders’ Equity | 412.854 | 413.556 | 429.019 | 456.174 | 441.305 |
Total Common Shares Outstanding | 341.663 | 305.573 | 294.948 | 282.86 | 266.74 |
Total Preferred Shares Outstanding | 0.03162 | 0.03162 | 0.03162 | 0.03162 | 0.03162 |
Korte Termijn Investeringen | 24.414 | 14.684 | 9.876 | 9.945 | 14.978 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
Geldmiddelen uit Operationele Activiteiten | -175.373 | 10.145 | -139.096 | -18.682 | -131.095 |
Geldmiddelen uit Operationele Activiteiten | 6.946 | 6.788 | 7.179 | 6.662 | 6.288 |
Deferred Taxes | |||||
Niet-Geldelijke Posten | 24.253 | 41.824 | 27.662 | 27.532 | 24.4914 |
Contant Betaalde Rente | 1.143 | 1.152 | 1.176 | 1.224 | 1.17109 |
Veranderingen in het Operationeel Kapitaal | 24.084 | -9.743 | 8.954 | 58.684 | 0.17005 |
Geldmiddelen uit Investeringsactiviteiten | -33.61 | -43.15 | -4.441 | -4.657 | -3.59092 |
Kapitaaluitgaven | -53.062 | -33.814 | -3.466 | -4.657 | -3.59711 |
Overige Cash Flow investeringsposten, Totaal | 19.452 | -9.336 | -0.975 | 0 | 0.00619 |
Geldmiddelen uit Financieringsactiviteiten | 95.83 | 225.264 | 183.855 | 31.323 | 128.285 |
Financiering van Cash Flow Posten | 0 | -1.542 | 0 | 204.384 | |
Uitgifte (Aflossing) van aandelen, netto | 96.32 | 228.123 | 180.89 | 31.643 | 86.0315 |
Uitgifte (Aflossing) van Schulden, Netto | -0.49 | -1.317 | 2.965 | -0.32 | -162.131 |
Wisselkoerseffecten | -0.104 | -0.164 | 0.379 | 0.77 | -0.73257 |
Nettowijziging in Geldmiddelen | -113.257 | 192.095 | 40.697 | 8.754 | -7.13309 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -70.893 | -230.656 | -156.554 | -99.839 | -50.604 |
Cash From Operating Activities | -58.526 | -175.373 | -128.035 | -95.844 | -52.391 |
Cash From Operating Activities | 2.562 | 6.946 | 5.057 | 3.35 | 1.66 |
Non-Cash Items | 3.267 | 24.253 | 21.364 | 10.1 | 1.775 |
Cash Interest Paid | 0.83 | 1.143 | 0.847 | 0.568 | 0.279 |
Changes in Working Capital | 6.538 | 24.084 | 2.098 | -9.455 | -5.222 |
Cash From Investing Activities | -11.489 | -33.61 | -27.227 | -11.591 | -7.533 |
Capital Expenditures | -1.842 | -53.062 | -38.716 | -22.996 | -4.544 |
Cash From Financing Activities | 56.25 | 95.83 | 72.057 | 43.834 | 16.038 |
Issuance (Retirement) of Stock, Net | 58.138 | 96.32 | 72.305 | 44.012 | 16.17 |
Issuance (Retirement) of Debt, Net | -1.888 | -0.49 | -0.248 | -0.178 | -0.132 |
Foreign Exchange Effects | -0.09 | -0.104 | -0.372 | 0.055 | -0.336 |
Net Change in Cash | -13.855 | -113.257 | -83.577 | -63.546 | -44.222 |
Other Investing Cash Flow Items, Total | -9.647 | 19.452 | 11.489 | 11.405 | -2.989 |
Financing Cash Flow Items | 0 | 0 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Deep Track Capital LP | Hedge Fund | 8.599 | 30000000 | 3000000 | 2023-03-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 7.4967 | 26154127 | 3550477 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.7575 | 23575361 | -653375 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5333 | 19304439 | 230102 | 2023-03-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 4.4805 | 15631235 | 1131235 | 2023-03-31 | LOW |
The Invus Group, LLC | Investment Advisor | 4.4805 | 15631235 | 15631235 | 2023-01-23 | |
Incyte Corp | Corporation | 3.4597 | 12070195 | -1992032 | 2021-12-31 | LOW |
Gilead Sciences Inc | Corporation | 3.1848 | 11111111 | 0 | 2021-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.3941 | 8352593 | 7310847 | 2023-03-31 | HIGH |
BofA Global Research (US) | Research Firm | 2.2831 | 7965277 | 6736276 | 2023-03-31 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 2.2475 | 7840900 | -1082400 | 2023-03-31 | HIGH |
Sofinnova Investments, Inc | Venture Capital | 1.8366 | 6407457 | 3513400 | 2023-03-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5839 | 5525794 | 276437 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.2803 | 4466719 | 582604 | 2023-03-31 | HIGH |
Oracle Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1308 | 3945110 | -945762 | 2023-03-31 | MED |
Goldman Sachs & Company, Inc. | Research Firm | 0.9187 | 3204963 | 1408257 | 2023-03-31 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6861 | 2393792 | 23523 | 2023-03-31 | LOW |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 0.6253 | 2181509 | 431670 | 2023-03-31 | MED |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.6072 | 2118418 | 14536 | 2023-03-31 | LOW |
SELECTRA Management Company S.A. | Investment Advisor | 0.6019 | 2100000 | 1520000 | 2022-06-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agenus Company profile
Over Agenus
Agenus Inc. is een immuno-oncologisch (I-O) bedrijf in een klinische fase. Het heeft een pijplijn van immuuncheckpoint-antilichamen, adoptieve celtherapieën en neoantigen kankervaccins, om kanker te bestrijden. Zijn I-O activa omvatten therapeutica op basis van antilichamen, monospecifieke en bispecifieke antilichamen, celtherapie, vaccins en adjuvanten. De antilichaamkandidaten zijn Balstilimab (een anti-PD-1 antilichaam) en Zalifrelimab (een anti-CTLA-4 antilichaam), dat zich in Fase 2 studies bevindt als zowel een monotherapie (balstilimab) als een combinatietherapie (balstilimab/zalifrelimab) voor de behandeling van patiënten met tweedelijns baarmoederhalskanker. De portefeuille van activa in klinische fase omvat ook botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 en AGENT 797. Het ontwikkelt gepersonaliseerde vaccins, namelijk Prophage en AutoSynVax, en off-the-shelf vaccins PhosphoSynVax, dat heat shock-eiwitten bevat om neoantigenen bij de juiste immuuncellen af te leveren om een immuunrespons tegen kanker te activeren.
Industry: | Biotechnology & Medical Research (NEC) |
3 Forbes Rd
LEXINGTON
MASSACHUSETTS 02421-7305
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen